Imexpharm Corporation (HOSE:IMP)

Imexpharm Balance Sheet

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	173,644	161,983	106,201	178,845	271,273	85,269
Short-Term Investments	222,102	142,000	93,000	211,300	111,300	60,340
Trading Asset Securities	-	-	-	-	1,153	3,268
Cash & Short-Term Investments	395,746	303,983	199,201	390,145	383,726	148,877
Cash Growth	46.35%	52.60%	-48.94%	1.67%	157.75%	85.58%
Accounts Receivable	440,176	334,746	254,058	228,770	241,946	328,134
Other Receivables	16,219	4,030	4,066	-1,000	11,995	17,650
Receivables	456,395	338,776	258,124	227,770	255,941	345,784
Inventory	752,433	705,082	699,446	435,841	492,075	424,237
Prepaid Expenses	13,786	15,564	6,539	1,601	3,155	2,031
Other Current Assets	41,756	46,139	43,825	48,195	41,443	61,046
Total Current Assets	1,660,116	1,409,544	1,207,135	1,103,553	1,176,340	981,975
Property, Plant & Equipment	765,591	828,489	908,754	996,450	955,680	949,147
Long-Term Investments	66,959	66,959	71,284	71,290	50,962	51,669
Other Intangible Assets	73,888	74,219	74,150	72,978	73,581	76,563
Other Long-Term Assets	400,882	125,566	131,293	32,672	38,136	37,101
Total Assets	2,967,435	2,504,777	2,392,615	2,276,944	2,294,700	2,096,455
Accounts Payable	154,166	77,044	70,505	87,542	92,713	59,704
Accrued Expenses	128,681	89,231	144,776	139,803	100,346	112,446
Short-Term Debt	202,946	86,122	49,422	-	80,491	130,928
Current Portion of Long-Term Debt	-	-	-	94,980	91,652	-
Current Income Taxes Payable	-	31,631	19,107	25,382	17,141	12,688
Current Unearned Revenue	62,090	-	-	-	-	-
Other Current Liabilities	43,519	37,630	24,227	34,789	26,295	31,167
Total Current Liabilities	591,402	321,657	308,036	382,497	408,638	346,932
Long-Term Debt	170,000	-	-	-	91,652	-
Other Long-Term Liabilities	7,000	-	-	-	-	19,037
Total Liabilities	768,402	321,657	308,036	382,497	500,290	365,969
Common Stock	1,540,428	1,540,428	700,384	667,054	667,054	667,054
Additional Paid-In Capital	187,323	187,323	507,368	507,368	507,368	507,368
Retained Earnings	469,219	453,306	874,764	717,963	617,926	554,002
Treasury Stock	-358.6	-358.6	-358.6	-358.6	-358.6	-358.6
Comprehensive Income & Other	2,421	2,421	2,421	2,421	2,421	2,421
Shareholders' Equity	2,199,033	2,183,119	2,084,579	1,894,447	1,794,410	1,730,486
Total Liabilities & Equity	2,967,435	2,504,777	2,392,615	2,276,944	2,294,700	2,096,455
Total Debt	372,946	86,122	49,422	94,980	263,795	130,928
Net Cash (Debt)	22,800	217,862	149,779	295,165	119,931	17,949
Net Cash Growth	-86.28%	45.46%	-49.26%	146.11%	568.18%	-57.91%
Net Cash Per Share	134.25	1414.60	972.53	1916.53	778.71	119.94
Filing Date Shares Outstanding	179.23	154.01	154.01	154.01	154.01	154.01
Total Common Shares Outstanding	179.23	154.01	154.01	154.01	154.01	154.01
Working Capital	1,068,713	1,087,886	899,099	721,056	767,702	635,043
Book Value Per Share	12269.00	14175.27	13535.33	12300.70	11651.16	11236.10
Tangible Book Value	2,125,145	2,108,900	2,010,429	1,821,469	1,720,829	1,653,923
Tangible Book Value Per Share	11856.76	13693.36	13053.86	11826.85	11173.39	10738.97
Buildings	-	384,650	384,597	299,061	298,602	262,381
Machinery	-	1,088,549	1,066,310	638,041	601,972	578,380
Construction In Progress	34,332	43,897	47,351	580,743	519,463	522,447

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.